Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company J B Chemicals & Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: JB Pharma recorded revenue growth of 10% to Rs 949 crore Operating EBITDA registered YoY growth of 15% to Rs 240 crore; Operating EBITDA margins were at 25.3% (YoY improvement of 90 bps) Gross Profit improved by 12% to Rs 628 crore Despite the in-licensed opthal business which has limited margins, Gross Profit margins witnessed YoY improvement of 90 bps, reaching 66.1% Due to tight control on overheads, other expenses as percentage to sales reduced by 80 bps to 23.7% Depreciation increased to Rs 46 crore as compared to Rs 41 crore Finance cost reduced to Rs 1 crore vs Rs 9 crore on account of debt repayment during the year Other income was at Rs 14 crore vs Rs 17 crore PAT increased to Rs 146 crore in Q4FY25, recording YoY growth of 15% FY25 Financial Highlights: Total revenue for the organization grew 12% to Rs 3,918 crore Operating EBITDA surpassed Rs 1,000 crore for the first time to Rs 1,087 crore (YoY growth of 16%); Operating EBITDA margins improved by 70 bps to 27.7% Gross Margin witnessed improvement of 30 bps to 66.4% as compared to 66.1 % Non-cash ESOP costs was at Rs 55 crore v/s Rs 42 crore Other Expenses as a percentage to sales witnessed YoY improvement of 60 bps to 22.5% in FY25 Depreciation increased to Rs 171 crore from Rs 138 crore on account of amortization of acquired/inlicensed brands Effective tax rate for the year was 25.9% as compared to 26.5% Net Profit increased by 19% to Rs 660 crore Commenting on the financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned, “We have closed the financial year FY25 on a strong note, in line with our strategic intent and sustained execution in the market. Our Domestic business continues to be one of the fastest growing in IPM. We have built a strong foundation over the last five years. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward. The CDMO business which is another focus area bounced back strongly in second half of the year. Together our Domestic and CDMO business now constitute 69% of overall revenues - Both businesses enjoy high ROCEs & high operating margins and contributed strongly towards enhancing profitability of the organisation. Our outlook on growth is based on expansion within Domestic and CDMO businesses, as we have outlined consistently. A number of factors drive this growth include building on our existing brand franchises within India & executing key marquee projects in CDMO. We are confident therefore of charting superior growth and delivering improved profitability in the medium to longer term. Result PDF